Clinical Trial Results:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients with Primary Hypercholesterolemia Not Treated With a Statin
Summary
|
|
EudraCT number |
2013-002659-14 |
Trial protocol |
BE NL ES DK |
Global end of trial date |
|
Results information
|
|
Results version number |
v1 |
This version publication date |
09 Feb 2017
|
First version publication date |
09 Feb 2017
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
EFC13786
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02023879 | ||
WHO universal trial number (UTN) |
U1111-1146-3517 | ||
Other trial identifiers |
Study Name: ODYSSEY CHOICE II | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi aventis recherche & développement
|
||
Sponsor organisation address |
1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
|
||
Public contact |
Trial Transparency Team, Sanofi aventis recherche & développement
, Contact-US@sanofi.com
|
||
Scientific contact |
Trial Transparency Team, Sanofi aventis recherche & développement
, Contact-US@sanofi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
27 Nov 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
27 Oct 2014
|
||
Global end of trial reached? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen including an alirocumab starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background therapy or as monotherapy in comparison with placebo in subjects with primary hypercholesterolemia not treated with a statin.
|
||
Protection of trial subjects |
Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.
|
||
Background therapy |
All subjects were to maintain a stable diet throughout the entire study duration, including the screening period. Subjects receiving background non-statin lipid modifying therapy (LMT) (ezetimibe or fenofibrate) had to continue their treatment without change (including dose) from screening through the end of 24-week double-blind treatment period barring exceptional circumstances. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Dec 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 56
|
||
Country: Number of subjects enrolled |
Spain: 28
|
||
Country: Number of subjects enrolled |
Belgium: 12
|
||
Country: Number of subjects enrolled |
Denmark: 21
|
||
Country: Number of subjects enrolled |
Australia: 12
|
||
Country: Number of subjects enrolled |
Canada: 27
|
||
Country: Number of subjects enrolled |
New Zealand: 6
|
||
Country: Number of subjects enrolled |
United States: 71
|
||
Worldwide total number of subjects |
233
|
||
EEA total number of subjects |
117
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
125
|
||
From 65 to 84 years |
104
|
||
85 years and over |
4
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
The study was conducted at 43 centers in 8 countries. A total of 402 subjects screened between December, 2013 and May, 2014, of whom 233 subjects were randomized and 169 were screen failures. Screen failures were mainly due to exclusion criteria met. | ||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||
Screening details |
Randomization was stratified by statin intolerant status and background therapy (non-statin lipid therapy vs diet). Randomization followed a 1:2:1 ratio for placebo, alirocumab 75 mg and alirocumab 150 mg instead of 1:1:2 as initially planned due to systematic error in treatment allocation algorithm discovered after all subjects were randomized. | ||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Core Study Period (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer | ||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo Q2W | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Placebo (for alirocumab) every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL subcutaneous injection in the abdomen, thigh or outer area of the upper arm by self-injection or by another designated person using the auto-injector.
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Alirocumab 75 mg Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted low-density lipoprotein cholesterol (LDL-C) levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Alirocumab
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
SAR236553, REGN727
|
||||||||||||||||||||||||||||||||||||||||||||
Other name |
Praluent®
|
||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL subcutaneous injection in the abdomen, thigh or outer area of the upper arm by self-injection or by another designated person using the auto-injector.
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Alirocumab 150 mg Q4W/Up to 150 mg Q2W | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Alirocumab 150 mg Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Alirocumab
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
SAR236553, REGN727
|
||||||||||||||||||||||||||||||||||||||||||||
Other name |
Praluent®
|
||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
1 ml subcutaneous injection in the abdomen, thigh or outer area of the upper arm by self-injection or by another designated person using the auto-injector.
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL subcutaneous injection in the abdomen, thigh or outer area of the upper arm by self-injection or by another designated person using the auto-injector.
|
||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Q2W
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo (for alirocumab) every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Alirocumab 75 mg Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted low-density lipoprotein cholesterol (LDL-C) levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Alirocumab 150 mg Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo Q2W
|
||
Reporting group description |
Placebo (for alirocumab) every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks. | ||
Reporting group title |
Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)
|
||
Reporting group description |
Alirocumab 75 mg Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted low-density lipoprotein cholesterol (LDL-C) levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. | ||
Reporting group title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W
|
||
Reporting group description |
Alirocumab 150 mg Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C at Week 24 Intent-to-Treat (ITT Analysis) | ||||||||||||||||
End point description |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis). ITT population that included all randomized subjects with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Alirocumab 150 mg Q4W/up to 150 mg Q2W was compared to placebo group using an appropriate contrast statement.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [1] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Least square (LS) mean difference | ||||||||||||||||
Point estimate |
-56.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-62.9 | ||||||||||||||||
upper limit |
-49.9 | ||||||||||||||||
Notes [1] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population that included all randomized and treated subjects with one baseline and at least one post-baseline calculated LDL-C value on-treatment.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
A hierarchical testing procedure was used to control type I error and handle multiple secondary endpoint analyses. Testing was then performed sequentially in the order the endpoints are reported. The hierarchical testing sequence continued only when previous endpoint was statistically significant at 0.05 level.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [2] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-59.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-65.6 | ||||||||||||||||
upper limit |
-53.8 | ||||||||||||||||
Notes [2] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [3] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-44.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-51.8 | ||||||||||||||||
upper limit |
-38.1 | ||||||||||||||||
Notes [3] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [4] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-48.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-54.8 | ||||||||||||||||
upper limit |
-41.9 | ||||||||||||||||
Notes [4] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [5] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-55.5
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-61.1 | ||||||||||||||||
upper limit |
-49.8 | ||||||||||||||||
Notes [5] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points. mITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [6] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-58.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-63.8 | ||||||||||||||||
upper limit |
-53.4 | ||||||||||||||||
Notes [6] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population. Number of subjects analyzed = subjects of the ITT population with available data at specified time-points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
114
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [7] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-46.4
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-52.4 | ||||||||||||||||
upper limit |
-40.4 | ||||||||||||||||
Notes [7] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population. Number of subjects analyzed = subjects of the mITT population with available data at specified time-points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
108
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [8] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-48.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-54.3 | ||||||||||||||||
upper limit |
-42.8 | ||||||||||||||||
Notes [8] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [9] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-49
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-54.9 | ||||||||||||||||
upper limit |
-43.2 | ||||||||||||||||
Notes [9] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [10] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-51.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-57.1 | ||||||||||||||||
upper limit |
-46.4 | ||||||||||||||||
Notes [10] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Total-C at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [11] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-35.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-39.8 | ||||||||||||||||
upper limit |
-30.8 | ||||||||||||||||
Notes [11] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population. Number of subjects analyzed = subjects of the ITT population with available data at specified time-points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
114
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [12] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-38.2
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-44.3 | ||||||||||||||||
upper limit |
-32.1 | ||||||||||||||||
Notes [12] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [13] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-37.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-43.9 | ||||||||||||||||
upper limit |
-31.8 | ||||||||||||||||
Notes [13] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant).
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [14] | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-26.3
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-30.9 | ||||||||||||||||
upper limit |
-21.7 | ||||||||||||||||
Notes [14] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percentage of Very High Cardiovascular (CV) Risk Subjects Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Subjects Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and <5%.
High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia.
Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion >50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage.
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a multiple imputation approach followed by a logistic regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [15] | ||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||
Point estimate |
279.8
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
29.1 | ||||||||||||||||
upper limit |
2690.1 | ||||||||||||||||
Notes [15] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percentage of Very High CV Risk Subjects Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Subjects Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis | ||||||||||||||||
End point description |
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a multiple imputation approach followed by logistic regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [16] | ||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||
Point estimate |
354.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
36.2 | ||||||||||||||||
upper limit |
3479.5 | ||||||||||||||||
Notes [16] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percentage of Subjects Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a LOCF approach followed by logistic regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [17] | ||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||
Point estimate |
126
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
20 | ||||||||||||||||
upper limit |
9999 | ||||||||||||||||
Notes [17] - Threshold for significance at 0.05 level. Confidence interval should be read as 20.0 to >9999. |
|
|||||||||||||||||
End point title |
Percentage of Subjects Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis | ||||||||||||||||
End point description |
Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a LOCF approach followed by logistic regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
113
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.0001 [18] | ||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||
Point estimate |
141.5
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
22.2 | ||||||||||||||||
upper limit |
9999 | ||||||||||||||||
Notes [18] - Threshold for significance at 0.05 level. Confidence interval should be read as 20.0 to >9999. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a Multiple imputation approach followed by robust regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.0002 [19] | ||||||||||||||||
Method |
Regression, Robust | ||||||||||||||||
Parameter type |
Adjusted mean difference | ||||||||||||||||
Point estimate |
-19.6
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-29.8 | ||||||||||||||||
upper limit |
-9.4 | ||||||||||||||||
Notes [19] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W vs. Placebo | ||||||||||||||||
Statistical analysis description |
Testing according to the hierarchical testing procedure (only performed if the previous endpoint was statistically significant). Statistical analysis used a Multiple imputation approach followed by robust regression model.
|
||||||||||||||||
Comparison groups |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W v Placebo Q2W
|
||||||||||||||||
Number of subjects included in analysis |
115
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.0892 [20] | ||||||||||||||||
Method |
Regression, Robust | ||||||||||||||||
Parameter type |
Adjusted mean difference | ||||||||||||||||
Point estimate |
-7.9
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-17.1 | ||||||||||||||||
upper limit |
1.2 | ||||||||||||||||
Notes [20] - Threshold for significance at 0.05 level. |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population. Number of subjects analyzed = subjects of the ITT population with available data at specified time-points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | ||||||||||||||||
End point description |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population. Number of subjects analyzed = subjects of the ITT population with available data at specified time-points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
From Baseline to Week 24
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All Adverse Events (AEs) were collected from signature of the informed consent form up to the primary completion date (32 weeks) regardless of seriousness or relationship to investigational medicinal product (IMP).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Reported AEs & deaths are treatment-emergent, i.e.,AEs developed/worsened & deaths that occurred "on-treatment" (from 1st dose of double-blind injection up to day of last dose[active or placebo depending on Q2W or Q4W regimen]+70 days or up to the day before the first injection in open-label extension period for subjects entering extension period).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Q2W
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects exposed to placebo SC injection Q2W added to stable non-statin LMT or diet alone (mean exposure of 23 weeks). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alirocumab 150 mg Q4W/Up to 150 mg Q2W
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects exposed to alirocumab 150 mg Q4W/up to 150 mg Q2W SC injection added to stable non-statin LMT or diet alone (mean exposure of 22 weeks). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects exposed to alirocumab 75 mg Q2W/up to 150 mg Q2W SC injection added to stable non-statin LMT or diet alone (mean exposure of 23 weeks). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
18 Oct 2013 |
-Changes were made to the exclusion criterion for consistency with the 2004 adult treatment panel (ATP) III guidelines. -Timing of the primary endpoint was changed (at Week 24, to be consistent with the rest of the phase 3 program). –Changes were made to the analysis of the primary and secondary endpoints (use of an ITT approach). -Added collection of measured LDL-C at Week 0 and Week 24. |
||
25 Aug 2014 |
-Adjusted the list of key and other secondary efficacy endpoints and estimands (ITT estimand and on-treatment estimand). -Added time points (Week 9, Week 10 and Week 11) in the model for the primary efficacy analysis endpoint. -Specified sensitivity analyses to be performed on the primary efficacy endpoint. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
The systematic randomization error was not anticipated to have an impact on the power of the study. The sample size to detect a difference in efficacy endpoints was reached (it was increased to obtain additional safety data) and blind was maintained. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/27625344 |